Company & Sponsor Intelligence

Teva Branded Pharmaceutical Products R&D, Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials10

Recruiting0

Completed10

Countries1

Therapeutic footprint

alzheimersepilepsyhuntingtonsmultiple_sclerosispain_neuropathyparkinsons

Indexed studies

NCT00936676ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
parkinsons · United StatesCOMPLETED

NCT00104273Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
alzheimers · United StatesPHASE2

NCT00203112Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
multiple_sclerosis · PHASE2

NCT00202982A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
multiple_sclerosis · United StatesPHASE2

NCT01223365Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
pain_neuropathy · United StatesPHASE3

NCT00034814Multicenter Trial for Adults With Partial Seizures
epilepsy · PHASE2

NCT00203138Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
parkinsons · PHASE3

NCT00724048A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
huntingtons · United StatesPHASE2

NCT00203125A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.
parkinsons · PHASE3

NCT00932581Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties
parkinsons · COMPLETED

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →